Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
KalVista Pharmaceuticals ( (KALV) ) has issued an update.
On October 1, 2025, KalVista Pharmaceuticals appointed Bethany Sensenig to its Board of Directors and Audit Committee, with Nancy Stuart transitioning to the Compensation Committee. This strategic move aims to leverage Ms. Sensenig’s financial and operational expertise as the company continues to expand the global reach of EKTERLY, its innovative therapy for hereditary angioedema.
The most recent analyst rating on (KALV) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company’s strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock’s score reflects financial struggles counterbalanced by strategic opportunities.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals is a global pharmaceutical company focused on delivering oral therapies for rare diseases with unmet needs. The company developed EKTERLY, the first oral on-demand treatment for hereditary angioedema (HAE), and collaborates with the global HAE community to enhance treatment and care.
Average Trading Volume: 1,318,138
Technical Sentiment Signal: Sell
Current Market Cap: $608.8M
Find detailed analytics on KALV stock on TipRanks’ Stock Analysis page.